The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy

被引:2
作者
Modiano, JF
Ritt, MG
Wojcieszyn, J
机构
[1] Texas A&M Univ, Coll Vet Med, Dept Pathobiol, College Stn, TX USA
[2] Texas A&M Univ, Coll Vet Med, Dept Small Anim Med & Surg, College Stn, TX USA
关键词
apoptosis; gene therapy; immunophenotyping; immunotherapy; oncogenes; tumor suppressor genes;
D O I
10.1892/0891-6640(1999)013<0163:TMBOCM>2.3.CO;2
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Melanoma is a common neoplastic disease of dogs with variable presentation and biological behavior Canine malignant melanoma is a rapidly metastatic disease that generally is incurable. The loss of function of cellular safeguards built into the genetic program and of immune surveillance systems that cooperate to prevent tumor formation and progression appear to be important underlying causes of canine malignant melanoma. In effect, many existing cancer treatments restore the function of 1 or the other of these mechanisms. For example, chemotherapy and radiotherapy often kill tumor cells by initiating a genetic suicide mechanism (apoptosis), and immunotherapy initiates or enhances a response by the body's immune cells to identify and destroy cancer cells by mechanisms that rely on direct cytotoxicity or apoptotic cell death. Nevertheless, standard therapeutic approaches have not proved effective in treatment of canine malignant melanoma, with only marginal improvement in the outcome of dogs with this disease. The advantages of an improved understanding of the molecular basis of canine cancer are underscored by recent promising advances in diagnosis and in immunologic and genetic therapies that may help reduce the mortality of dogs affected with malignant melanoma.
引用
收藏
页码:163 / 174
页数:12
相关论文
共 140 条
  • [21] In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma
    Dow, SW
    Elmslie, RE
    Willson, AP
    Roche, L
    Gorman, C
    Potter, TA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) : 2406 - 2414
  • [22] Dummer W, 1996, INT J CANCER, V66, P607, DOI 10.1002/(SICI)1097-0215(19960529)66:5<607::AID-IJC4>3.3.CO
  • [23] 2-B
  • [24] EASTHAM JA, 1995, CANCER RES, V55, P5151
  • [25] ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301
  • [26] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [27] Genetic immunotherapy for cancer
    Elmslie, RE
    Dow, SW
    [J]. SEMINARS IN VETERINARY MEDICINE AND SURGERY-SMALL ANIMAL, 1997, 12 (03): : 193 - 205
  • [28] ELMSLIE RE, 1995, P ANN M VET CANC SOC, V15, P52
  • [29] APOPTOSIS AND THE CELL-CYCLE
    EVAN, GI
    BROWN, L
    WHYTE, M
    HARRINGTON, E
    [J]. CURRENT OPINION IN CELL BIOLOGY, 1995, 7 (06) : 825 - 834
  • [30] Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population
    FitzGerald, MG
    Harkin, DP
    SilvaArrieta, S
    MacDonald, DJ
    Lucchina, LC
    Unsal, H
    ONeill, E
    Koh, J
    Finkelstein, DM
    Isselbacher, KJ
    Sober, AJ
    Haber, DA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) : 8541 - 8545